Gene Therapy for Hemophilia: From Hemgenix to a One-Time Cure

The Promise of a Single Injection

For decades, hemophilia has been one of the most talked-about targets for gene therapy. The logic is straightforward: hemophilia is caused by a single missing protein. Deliver a working gene that produces that protein, and the disease should be corrected. In theory, a one-time infusion could replace a lifetime of intravenous clotting factor injections that cost hundreds of thousands of dollars per year.

That theory has now been tested in the real world. In November 2022, the FDA approved Hemgenix (etranacogene dezaparvovec), a gene therapy for hemophilia B developed by CSL Behring. Its price tag of $3.5 million made it the most expensive drug in the world. A year earlier, BioMarin's Roctavian (valoctocogene roxaparvovec) had been conditionally approved in Europe for hemophilia A, only to be voluntarily withdrawn from the European market in 2024 amid disappointing durability data and near-zero commercial uptake. In 2024, Pfizer's Beqvez (fidanacogene elaparvovec) joined the hemophilia B gene therapy landscape with its own FDA approval.

The story of gene therapy for hemophilia is not a simple tale of scientific triumph. It is a story of remarkable biology, stubborn commercial realities, and unresolved questions about how long these therapies actually last.

Understanding Hemophilia

Hemophilia is a group of inherited bleeding disorders caused by deficiencies in specific clotting factors — proteins that work together in a cascade to form blood clots and stop bleeding. Without adequate levels of these proteins, even minor injuries can lead to prolonged bleeding. Spontaneous bleeding into joints, muscles, and internal organs is common in severe cases and can be debilitating or life-threatening.

Hemophilia A vs. Hemophilia B

Hemophilia A is caused by deficiency or dysfunction of Factor VIII (FVIII). It accounts for roughly 80% of all hemophilia cases and affects approximately 1 in 5,000 male births. The F8 gene is located on the X chromosome, which is why the condition overwhelmingly affects males — females with one defective copy are typically carriers.

Hemophilia B, sometimes called Christmas disease (named after Stephen Christmas, the first patient described with the condition in 1952), is caused by deficiency of Factor IX (FIX). It is less common, affecting about 1 in 25,000 male births. The F9 gene is also X-linked.

Both types are classified by severity:

Severe: Less than 1% of normal factor levels. Patients experience spontaneous bleeding episodes, often into joints (hemarthrosis), leading to chronic joint damage, pain, and disability.
Moderate: 1-5% of normal factor levels. Bleeding after minor trauma; occasional spontaneous bleeds.
Mild: 5-40% of normal factor levels. Bleeding typically only after surgery or significant injury.

A critical insight for gene therapy is that even modest increases in clotting factor levels — moving a patient from less than 1% to 5% or even 2-3% — can dramatically reduce spontaneous bleeding events and transform quality of life. The bar for clinical success does not require restoring factor levels to the normal range (50-150%). It requires getting them above the threshold where spontaneous bleeding stops.

The Burden of Current Treatment

The standard treatment for hemophilia is replacement therapy: regular intravenous infusions of the missing clotting factor. For severe hemophilia A, this typically means infusing recombinant Factor VIII two to three times per week. For hemophilia B, recombinant Factor IX is infused once or twice weekly due to its longer half-life.

This prophylactic regimen prevents most spontaneous bleeds but imposes an enormous burden on patients. Children must learn to self-infuse at a young age. Adults spend hours each week on infusions. Venous access can become difficult over years of repeated injections. And despite prophylaxis, breakthrough bleeds still occur.

The financial burden is staggering. Annual treatment costs for severe hemophilia in the United States range from $200,000 to $300,000 for standard factor replacement. For patients who develop inhibitors — antibodies that neutralize the infused clotting factor, which occurs in about 30% of severe hemophilia A patients — costs can exceed $1 million per year, as they require bypassing agents or immune tolerance induction therapy.

Extended half-life products, subcutaneous therapies like emicizumab (Hemlibra) for hemophilia A, and other non-factor therapies have improved convenience and outcomes. But none of them are cures. They all require ongoing treatment for life.

This is the landscape into which gene therapy arrived.

The AAV Vector Approach

Nearly all hemophilia gene therapies in clinical development use adeno-associated virus (AAV) vectors to deliver a functional copy of the clotting factor gene to the liver, where clotting factors are naturally produced.

AAV is a small, non-pathogenic virus that has become the workhorse of in vivo gene therapy. It does not integrate into the host genome in most cases (the delivered gene typically remains as an episomal DNA circle in the cell nucleus). Different serotypes of AAV have different tissue tropisms — AAV5, AAV8, and AAVrh10, among others, are used for liver-directed gene therapy because they efficiently transduce hepatocytes.

The basic approach is conceptually simple:

A functional copy of the clotting factor gene is packaged inside an AAV capsid
The vector is administered as a single intravenous infusion
The AAV particles travel to the liver and enter hepatocytes
The delivered gene is expressed, and the liver cells begin producing the missing clotting factor
The clotting factor is secreted into the bloodstream

For hemophilia B, the Factor IX gene is small enough (~1.4 kb coding sequence) to fit comfortably within the AAV packaging capacity (~4.7 kb). Researchers have used a hyperactive variant of FIX called FIX-Padua (R338L), which has 5-8 times the clotting activity of wild-type FIX, allowing lower expression levels to achieve therapeutic benefit.

Hemophilia A presents a greater challenge. The Factor VIII gene is large (~7 kb coding sequence), exceeding AAV's packaging capacity. Researchers solved this by engineering a B-domain-deleted variant of FVIII (BDD-FVIII), which removes a large, functionally dispensable region of the protein and reduces the coding sequence to approximately 4.4 kb — just barely fitting within the AAV vector.

Key Challenges with AAV

Despite the elegance of the approach, AAV gene therapy faces several biological challenges:

Pre-existing immunity: A substantial fraction of the population has been naturally exposed to wild-type AAV and carries neutralizing antibodies. Patients with pre-existing antibodies against the specific AAV serotype used are excluded from treatment because the antibodies would destroy the vector before it reaches the liver. For AAV5, approximately 30-40% of the population has pre-existing antibodies, though the exclusion threshold varies by assay and study.

Immune response to the vector: Even in patients without pre-existing antibodies, the AAV capsid triggers an immune response after administration. This typically manifests as an increase in liver enzymes (ALT) 4-12 weeks post-infusion, indicating hepatocyte damage. Immunosuppression with corticosteroids is standard for managing this response, but in some cases, the immune attack on transduced hepatocytes leads to a decline in factor expression.

Durability: Because AAV-delivered DNA is mostly episomal (not integrated into chromosomes), it is lost when hepatocytes divide. The liver has a slow turnover rate in adults, so expression can persist for years — but whether it will last a lifetime is an open question. This is the central uncertainty in hemophilia gene therapy.

One-shot limitation: After AAV administration, the patient develops high-titer antibodies against the AAV capsid. Re-dosing with the same serotype is currently not possible. If expression wanes, the patient cannot simply receive another infusion.

Hemgenix: The Most Expensive Drug in the World

Hemgenix (etranacogene dezaparvovec), developed by uniQure and commercialized by CSL Behring, became the first gene therapy approved in the United States for hemophilia B when it received FDA approval on November 22, 2022.

The Science

Hemgenix uses an AAV5 vector carrying a codon-optimized Padua variant of human Factor IX (FIX-Padua) under the control of a liver-specific promoter. The Padua variant is key: its enhanced specific activity means that even moderate expression levels translate into substantial clotting activity.

The therapy is administered as a single intravenous infusion. Patients receive immunosuppressive prophylaxis (typically corticosteroids) to manage the anticipated immune-mediated liver inflammation.

Clinical Trial Results

The pivotal HOPE-B trial (Phase III) enrolled 54 adult males with moderately severe to severe hemophilia B (FIX activity of 2% or below). Results were encouraging:

Mean Factor IX activity at 18 months post-infusion was approximately 36.9% of normal — well within the mild hemophilia range and above the threshold for spontaneous bleeding
Annualized bleeding rate (ABR) decreased by 64% compared to the lead-in prophylaxis period
Factor IX use was reduced by 97%, with the vast majority of patients discontinuing prophylactic infusions entirely
54% of treated patients reported zero bleeds in the year following infusion

Long-term follow-up from the earlier Phase II/III study showed that FIX activity levels, while declining from their peak, remained in the mild hemophilia range at 3+ years.

The Price

At $3.5 million per treatment, Hemgenix became the world's most expensive drug upon its approval. CSL Behring argued that the price was justified by value-based calculations: eliminating decades of prophylactic FIX replacement therapy (costing $200,000-$300,000 per year) would result in net savings over a patient's lifetime.

The Institute for Clinical and Economic Review (ICER) evaluated the cost-effectiveness and concluded that Hemgenix's price aligned with value-based benchmarks only under optimistic assumptions about durability — specifically, that factor levels would be maintained for 20+ years. If durability proves shorter, the cost-effectiveness argument weakens considerably.

Roctavian: The Cautionary Tale

BioMarin's Roctavian (valoctocogene roxaparvovec) tells a more complicated story. It targets hemophilia A — the more common form — using an AAV5 vector carrying a B-domain-deleted FVIII gene.

Regulatory Journey

Roctavian's path to market was turbulent:

2020: BioMarin submitted a Biologics License Application (BLA) to the FDA. The agency issued a Complete Response Letter, requesting two additional years of follow-up data from the Phase III GENEr8-1 trial to assess durability.
2022: The European Medicines Agency (EMA) granted conditional marketing authorization in Europe for the treatment of severe hemophilia A in adults without pre-existing AAV5 antibodies and without a history of FVIII inhibitors.
2023: BioMarin resubmitted to the FDA with additional data. The FDA approved Roctavian in June 2023 at a US list price of $2.9 million.
2024: BioMarin voluntarily withdrew Roctavian from the European market, citing poor commercial uptake and the challenging reimbursement environment.

The Durability Problem

The central challenge with Roctavian has been the declining Factor VIII expression over time. Data from the Phase I/II study (Study 270-201) showed:

Year 1: Mean FVIII activity was approximately 40-50% of normal in the high-dose cohort
Year 2: Mean levels declined to approximately 20-25%
Year 3: Further decline to approximately 10-15%
Year 4-5: Levels stabilized in some patients at approximately 5-15%, but with wide variability

In the Phase III GENEr8-1 trial, a similar pattern emerged. While most patients had clinically meaningful Factor VIII levels (above 5%) at two years, the declining trajectory raised concerns about long-term benefit.

The clinical impact of these declining levels was nuanced. Even as Factor VIII levels fell, treated patients continued to experience fewer bleeds than they had on prophylaxis. At year two of the Phase III trial, 80% of patients remained off prophylactic Factor VIII. But the declining curve made it difficult for payers to justify the $2.9 million price tag.

Why Does FVIII Expression Decline?

The reasons for declining FVIII expression in Roctavian-treated patients are not entirely understood, but several factors likely contribute:

Hepatocyte turnover: As liver cells divide, episomal AAV genomes are diluted. This affects all AAV gene therapies, but the larger and more immunogenic FVIII transgene may be more susceptible.
Immune-mediated loss: Ongoing low-grade immune surveillance may selectively eliminate transduced hepatocytes expressing the foreign FVIII protein.
Epigenetic silencing: The transgene promoter may undergo methylation or other epigenetic modifications that reduce expression over time.
FVIII biology: Factor VIII is inherently more difficult to express at stable levels than Factor IX. The protein is larger, less stable, requires more cellular machinery to produce, and is subject to more complex post-translational processing.

This last point helps explain why hemophilia B gene therapies have generally shown more stable, durable expression than hemophilia A gene therapies across multiple programs.

European Withdrawal

BioMarin's decision to withdraw Roctavian from Europe in 2024 was driven by commercial reality, not safety concerns. The therapy was conditionally approved, meaning BioMarin was required to submit additional follow-up data. But reimbursement negotiations with European payers were difficult. The durability concerns made national health authorities reluctant to pay a multi-million-dollar price for a therapy that might not deliver lifelong benefit.

Only a handful of patients in Europe received Roctavian commercially before the withdrawal. The episode sent a chill through the gene therapy industry and raised fundamental questions about the commercial viability of one-time, ultra-high-cost therapies.

Beqvez: Pfizer Enters the Field

In April 2024, the FDA approved Pfizer's Beqvez (fidanacogene elaparvovec) for hemophilia B in adults. Like Hemgenix, Beqvez uses an AAV vector (an AAV variant called AAVrh74var in some descriptions, though Pfizer's vector is proprietary) carrying a FIX-Padua transgene to deliver a functional copy of the Factor IX gene to the liver.

Clinical Data

The BENEGENE-2 Phase III trial enrolled 45 adult males with moderately severe to severe hemophilia B:

Mean Factor IX activity at one year was approximately 25% of normal, placing patients in the mild range
Annualized bleeding rate decreased by 71% compared to the FIX prophylaxis lead-in period
ABR of zero was achieved by 36 of 45 patients (80%) during the first year

Beqvez was priced at approximately $3.5 million, comparable to Hemgenix. The durability data available at approval was more limited than for Hemgenix, but early trends were consistent with stable expression in the mild range.

The competitive dynamics between Hemgenix and Beqvez for the hemophilia B gene therapy market are unusual. With a relatively small patient population (approximately 3,000-4,000 males with moderate or severe hemophilia B in the US, many of whom have pre-existing AAV antibodies), two competing products at identical price points face a challenging commercial environment.

Sangamo and the Broader Pipeline

Beyond the three approved products, several other gene therapy programs for hemophilia have been or remain in development.

Sangamo Therapeutics pursued a differentiated approach with its hemophilia A program, SB-525 (giroctocogene fitelparvovec), developed in partnership with Pfizer. This program used an AAV6 vector with a proprietary liver-specific promoter designed to drive more robust and durable FVIII expression. Sangamo's preclinical and early clinical data showed high FVIII expression levels. However, the program faced setbacks and Pfizer eventually took over full development. The Phase III AFFINE trial read out data showing meaningful FVIII activity, but durability remained a question. As of early 2026, the regulatory path forward remains under discussion.

Spark Therapeutics (a Roche subsidiary) developed SPK-8011, an AAV-LK03-based gene therapy for hemophilia A, and SPK-9001 for hemophilia B (the precursor to what eventually became a licensed product). These programs explored alternative AAV capsids that might have lower pre-existing immunity in the population.

Biomarin continues to follow treated patients in long-term studies even after the European withdrawal, and Roctavian remains available in the United States, though commercial uptake has been modest.

Several academic and biotech programs are exploring next-generation approaches, including:

Engineered capsids with reduced immunogenicity and enhanced liver tropism
Non-viral delivery platforms (lipid nanoparticles, transposons) that would allow re-dosing
In vivo genome editing to insert the clotting factor gene directly into a safe harbor locus in the genome, potentially enabling permanent, heritable correction
Immune evasion strategies to prevent or mitigate the anti-AAV immune response

Commercial Challenges: The Gene Therapy Business Model Problem

The commercial struggles of hemophilia gene therapy illuminate a broader crisis facing the gene therapy field. The fundamental tension is between one-time therapies and a healthcare payment system built around chronic treatment.

Payer Resistance

Insurance companies and national health systems are reluctant to pay multi-million-dollar prices for therapies with uncertain long-term durability. Their concerns are not unreasonable:

Durability uncertainty: Will a patient who receives gene therapy at age 25 still have therapeutic factor levels at age 50? At age 70? No one knows yet.
Budget impact: Even with a small patient population, a $3.5 million per-patient price creates significant budget impact in the years when patients present for treatment.
Alternative therapies: For hemophilia A, emicizumab (Hemlibra) has become a highly effective subcutaneous prophylaxis that patients and physicians are comfortable with. It is not a cure, but it dramatically reduces the treatment burden and costs less than gene therapy on an annual basis.
Outcomes-based agreements: Some payers have negotiated pay-for-performance contracts (e.g., installment payments contingent on continued factor expression), but these are complex to administer and few have been finalized.

Slow Uptake

Both Hemgenix and Roctavian experienced slower-than-expected commercial uptake after approval. Several factors contributed:

Physician conservatism: Hematologists who have managed hemophilia patients for decades are cautious about recommending an irreversible treatment with limited long-term data
Patient hesitancy: Many patients are well-controlled on current prophylaxis and are reluctant to accept the risks of gene therapy (including the immunosuppressive regimen and potential liver inflammation) for uncertain long-term benefit
Pre-existing antibodies: A significant portion of the eligible population is excluded due to anti-AAV antibodies
Treatment center infrastructure: Gene therapy administration and monitoring require specialized centers, and the number of qualified sites has been limited
Age restrictions: Current approvals are limited to adults, excluding the pediatric population where gene therapy could have the greatest lifetime impact (the episomal nature of AAV makes it less suitable for growing children whose liver cells are actively dividing)

CSL Behring reported modest Hemgenix revenues in 2023 and 2024, well below initial projections. BioMarin's decision to withdraw from Europe was partly driven by the same dynamics. These commercial outcomes have had a chilling effect on investment in gene therapy more broadly.

Durability: What the Long-Term Data Shows

The most important unanswered question in hemophilia gene therapy is durability. How long does the expression last?

The longest follow-up data comes from early academic trials:

Nathwani et al. (UCL/St. Jude): The pioneering AAV8-FIX trial for hemophilia B, first reported in the New England Journal of Medicine in 2011, has now accumulated over 10 years of follow-up in some patients. These patients received lower doses than are used in current commercial products, but the results are instructive:

Factor IX levels have remained stable at 2-7% of normal in most patients for over a decade
While these levels are modest, they have been sufficient to reduce or eliminate spontaneous bleeding in most patients
The stability of expression over 10+ years is reassuring and suggests that, at least for FIX in the liver, episomal AAV genomes can persist for extended periods in adults

BioMarin Phase I/II (Study 270-201): Long-term follow-up of Roctavian-treated patients shows that FVIII levels, after their initial decline, appear to stabilize in many patients at approximately 5-15% of normal. At 7+ years of follow-up, some patients maintain clinically meaningful levels — though significantly below their peak year-one values.

HOPE-B long-term data (Hemgenix): At 3+ years post-infusion, Factor IX activity levels in the HOPE-B cohort have declined from the initial mean of ~37% but remain in the range of 20-30% in most patients — still well within the mild hemophilia range.

These data suggest a pattern: factor levels peak in the first year, decline over the next 2-3 years, and then stabilize. Whether this stabilization represents a true plateau or merely a slow decline that will become apparent over decades remains to be seen. Only continued follow-up will provide the answer.

The Patient Perspective

For people living with hemophilia, the gene therapy era has brought both hope and complexity.

Many patients who have received gene therapy describe the experience as transformative. After a lifetime of planning activities around infusion schedules, carrying emergency clotting factor supplies, and living with the constant awareness that a fall or bump could trigger a dangerous bleed, the prospect of simply not having to think about hemophilia is profoundly meaningful.

Participants in the HOPE-B trial have described the freedom of traveling without factor supplies, exercising without fear, and experiencing what it feels like to have a normal blood clot form at a wound site — something most people take for granted.

But patients also describe anxiety. Gene therapy is irreversible — there is no going back. If factor levels decline, there is currently no option for re-dosing. Patients who choose gene therapy are making a one-time bet with incomplete information. Some patients who were well-controlled on emicizumab or extended half-life factor products have decided to wait for next-generation therapies rather than commit to the current options.

The hemophilia community is also grappling with equity concerns. Gene therapy is available only to adults, only to those without pre-existing AAV antibodies, and only in countries with the infrastructure and willingness to pay. Children with severe hemophilia — who arguably have the most to gain from a lifelong cure — are not currently eligible. Patients in low- and middle-income countries, where hemophilia treatment is often inadequate or unavailable, are unlikely to access $3.5 million gene therapies.

Where the Field Goes from Here

Despite the commercial headwinds, the science of hemophilia gene therapy continues to advance. Several directions are particularly promising:

Next-generation capsids: Engineered AAV capsids with improved liver tropism, reduced immunogenicity, and potentially the ability to evade pre-existing antibodies could expand the eligible patient population and improve durability.

Integration-competent approaches: Technologies that enable the transgene to integrate into a safe genomic locus (using zinc finger nucleases, CRISPR, or transposon systems) could solve the durability problem by making the genetic correction permanent and heritable through cell division.

Immune modulation: Novel immunosuppressive regimens or immune tolerance protocols could prevent the anti-AAV immune response, potentially enabling re-dosing and improving initial transduction efficiency.

Pediatric applications: As the safety profile of gene therapy becomes better established and integration-competent approaches mature, extending treatment to children could transform outcomes — intervening before joint damage accumulates.

Non-viral delivery: Lipid nanoparticle (LNP) delivery of mRNA or DNA encoding clotting factors, potentially combined with genome editing tools, could enable repeated dosing and avoid the AAV immunogenicity problem entirely.

The hemophilia gene therapy story is far from over. The first generation of approved products has proven that the concept works — a single infusion can convert severe hemophilia to mild hemophilia for at least several years. The next generation must solve durability, re-dosing, and access. Until then, gene therapy for hemophilia remains a remarkable but incomplete advance: a treatment that changes lives, but is not yet the lifelong cure it aspires to be.

Sources

Mahlangu, J. et al. "Etranacogene dezaparvovec (AMT-061) gene therapy for hemophilia B." New England Journal of Medicine, 2022.
Pipe, S.W. et al. "Trial of AAV5-hFVIII-SQ Gene Therapy in Hemophilia A (GENEr8-1)." New England Journal of Medicine, 2023.
Nathwani, A.C. et al. "Long-term safety and efficacy of factor IX gene therapy in hemophilia B." New England Journal of Medicine, 2014.
Nathwani, A.C. et al. "Adeno-associated virus vector-mediated gene transfer in hemophilia B." New England Journal of Medicine, 2011.
FDA Approval Letter — Hemgenix (etranacogene dezaparvovec), November 2022.
FDA Approval Letter — Roctavian (valoctocogene roxaparvovec), June 2023.
FDA Approval Letter — Beqvez (fidanacogene elaparvovec), April 2024.
EMA Withdrawal Assessment — Roctavian, 2024.
Institute for Clinical and Economic Review (ICER), "Gene Therapy for Hemophilia B and an Update on Gene Therapy for Hemophilia A: Effectiveness and Value." Final Evidence Report, 2022.
Mannucci, P.M. and Tuddenham, E.G.D. "The hemophilias — from royal genes to gene therapy." New England Journal of Medicine, 2001.
George, L.A. et al. "Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A." New England Journal of Medicine, 2021.
CSL Behring Hemgenix Prescribing Information, 2022.
BioMarin Investor Communications, 2024.
Pfizer Beqvez Prescribing Information, 2024.
World Federation of Hemophilia, Annual Global Survey, 2024.